BioNTech SE (NASDAQ:BNTX) Shares Acquired by Franklin Resources Inc.

Franklin Resources Inc. grew its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 3,942.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 136,786 shares of the company's stock after acquiring an additional 133,402 shares during the period. Franklin Resources Inc. owned about 0.06% of BioNTech worth $15,587,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of BNTX. abrdn plc increased its position in BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company's stock valued at $43,947,000 after purchasing an additional 159,676 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in BioNTech in the fourth quarter worth approximately $7,128,000. Charles Schwab Investment Management Inc. lifted its holdings in BioNTech by 39.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company's stock worth $21,349,000 after buying an additional 53,319 shares during the period. Flossbach Von Storch SE grew its stake in BioNTech by 1.1% during the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock worth $502,160,000 after buying an additional 47,236 shares during the last quarter. Finally, Exome Asset Management LLC acquired a new position in BioNTech during the 3rd quarter valued at about $4,104,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BNTX. HC Wainwright dropped their price target on BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. BMO Capital Markets boosted their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Finally, Morgan Stanley cut their price target on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $143.44.

Remove Ads

BioNTech Trading Up 3.7 %

BioNTech stock traded up $3.40 during midday trading on Friday, hitting $96.52. 1,149,784 shares of the stock were exchanged, compared to its average volume of 854,765. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock's 50-day simple moving average is $104.64 and its 200 day simple moving average is $111.67. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a market capitalization of $23.16 billion, a price-to-earnings ratio of -45.96 and a beta of 1.07.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business's revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. On average, equities analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.